Literature DB >> 15293572

T(11;18)-bearing pulmonary mucosa-associated lymphoid tissue lymphoma responding to cladribine.

Shigeru Kusumoto1, Yukio Kobayashi, Tetsuya E Tanimoto, Tatsuro Hasegawa, Yukiko Yokota, Kazuki Tanimoto, Naohiro Sekiguchi, Masaru Narabayashi, Takashi Watanabe, Yoshihiro Matsuno, Kensei Tobinai.   

Abstract

Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade B-cell lymphoma and is usually slow to disseminate. The t(11;18)(q21;q21) translocation has been identified in a subset of MALT lymphoma cases, and AP12 and MLT1/MALT1 genes have been implicated in this translocation. However, the clinicopathologic features of t(11;18)-bearing MALT lymphoma have not been fully elucidated, and the optimal therapy for patients with disseminating disease is unknown. We report an outstanding case of MALT lymphoma that showed massive pulmonary infiltration and leukemic transformation during a prolonged course of more than 16 years. Reverse transcriptase-polymerase chain reaction and dual-color fluorescence in situ hybridization analyses confirmed the existence of the AP12/MLT1 fusion gene in the lymphoma cells. Peripheral blood lymphoma cells disappeared after glucocorticoid therapy. Although the pulmonary lymphoma was slowly progressive and caused severe hypoxemia despite the continuation of glucocorticoid therapy, treatment with cladribine induced a marked reduction of pulmonary lymphomatous lesions and an improvement of the hypoxemia. These findings show the unique clinical features of this particular indolent B-cell lymphoma with t(11;18) translocation and suggest the potential therapeutic usefulness of glucocorticoid and cladribine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15293572     DOI: 10.1532/ijh97.03170

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

Review 1.  The pathogenetic role of oncogenes deregulated by chromosomal translocation in B-cell malignancies.

Authors:  Martin J S Dyer
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

2.  The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type.

Authors:  G Ott; T Katzenberger; A Greiner; J Kalla; A Rosenwald; U Heinrich; M M Ott; H K Müller-Hermelink
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

3.  Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma.

Authors:  Hongtao Ye; Hongxiang Liu; Ayoma Attygalle; Andrew C Wotherspoon; Andrew G Nicholson; Frederic Charlotte; Veronique Leblond; Paul Speight; John Goodlad; Anne Lavergne-Slove; Jose Ignacio Martin-Subero; Reiner Siebert; Ahmet Dogan; Peter G Isaacson; Ming-Qing Du
Journal:  Blood       Date:  2003-04-03       Impact factor: 22.113

4.  Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients.

Authors:  C Thieblemont; Y Bastion; F Berger; C Rieux; G Salles; C Dumontet; P Felman; B Coiffier
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

5.  The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas.

Authors:  J Dierlamm; M Baens; I Wlodarska; M Stefanova-Ouzounova; J M Hernandez; D K Hossfeld; C De Wolf-Peeters; A Hagemeijer; H Van den Berghe; P Marynen
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

6.  t(11;18)(q21;q21) is the most common translocation in MALT lymphomas.

Authors:  I A Auer; R D Gascoyne; J M Connors; F E Cotter; T C Greiner; W G Sanger; D E Horsman
Journal:  Ann Oncol       Date:  1997-10       Impact factor: 32.976

7.  Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

Authors:  Emanuele Zucca; Annarita Conconi; Ennio Pedrinis; Sergio Cortelazzo; Teresio Motta; Mary K Gospodarowicz; Bruce J Patterson; Andrés J M Ferreri; Maurilio Ponzoni; Liliana Devizzi; Roberto Giardini; Graziella Pinotti; Carlo Capella; Pier Luigi Zinzani; Stefano Pileri; Armando López-Guillermo; Elias Campo; Achille Ambrosetti; Luca Baldini; Franco Cavalli
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

8.  Detection of t(I 1; 18) in MALT-type lymphoma with dual-color fluorescence in situ hybridization and reverse transcriptase-polymerase chain reaction analysis.

Authors:  Y Kobayashi; M Nakata; M Maekawa; M Takahashi; H Fujii; Y Matsuno; M Fujishiro; H Ono; D Saito; T Takenaka; N Hirase; J Nishimura; T Akioka; K Enomoto; C Mikuni; T Hishima; M Fukayama; K Sugano; F Hosoda; M Ohki; K Tobinai
Journal:  Diagn Mol Pathol       Date:  2001-12

9.  Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.

Authors:  Annarita Conconi; Giovanni Martinelli; Catherine Thiéblemont; Andrés J M Ferreri; Liliana Devizzi; Fedro Peccatori; Maurilio Ponzoni; Ennio Pedrinis; Stefania Dell'Oro; Giancarlo Pruneri; Virginio Filipazzi; Pierre-Yves Dietrich; Alessandro M Gianni; Bertrand Coiffier; Franco Cavalli; Emanuele Zucca
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

10.  API2-MALT1 fusion defines a distinctive clinicopathologic subtype in pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

Authors:  Mitsukuni Okabe; Hiroshi Inagaki; Koichi Ohshima; Tadashi Yoshino; Chunmei Li; Tadaaki Eimoto; Ryuzo Ueda; Shigeo Nakamura
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

View more
  1 in total

1.  Detection of API2-MALT1 fusion transcripts in cytologic specimens of patients with pulmonary mucosa-associated lymphoid tissue lymphoma.

Authors:  Hiroshi Inagaki; Chunmei Li; Mitsukuni Okabe; Mitsunori Nishikawa; A Mitsunori Nishikawa; Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.